ZTS · 10-Q · 2026Q3 · Full report

Competition and Pricing Pressure

Zoetis Inc. · 2026-11-05 · Importance 43 · Surprise 32

U.S. companion animal revenue fell $329 million over the first nine months of 2026, as softer end-market demand coincided with heightened competition and persistent macroeconomic-driven price sensitivity. The key dermatology franchise and Simparica Trio faced competitive pressure, while generic competition affected Convenia and Cerenia. Lower Librela sales also contributed to the decline; in the third quarter, lower vaccine sales were an additional factor.

Key facts

• Zoetis’ companion-animal products faced softer end-market demand, increasing competition, and persistent macroeconomic-driven price sensitivity in the U.S. third quarter of 2026. source
• U.S. third-quarter 2026 companion-animal sales were also affected by generic competition on Convenia and Cerenia and lower sales of vaccines and Librela, partly offset by increased demand for small-animal diagnostics. source
• For the first nine months of 2026, U.S. companion-animal revenue decline reflected softer end-market demand, increased competition, and persistent macroeconomic-driven price sensitivity, including pressure on Zoetis’ key dermatology franchise and Simparica Trio. source
• U.S. first-nine-months 2026 companion-animal revenue was also affected by generic competition on Convenia and Cerenia and lower Librela sales. source
• Zoetis identified the possible impact and timing of competing products, including generic alternatives, and its ability to compete against them as risks to results. source